SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amid reactions to the Trump-Xi meeting, with no immediate announcements fueling speculation and volatility. The community is discussing potential outcomes related to tariffs, trade deals, and the broader impact on the market. Some traders are anticipating major market swings as details emerge.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is seeing increased social media activity, with community members actively discussing its potential, often alongside mentions of $SOL. Sentiment appears optimistic with frequent use of "WAGMI" (We Are All Going To Make It), while some users are pointing to potential pumps.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as traders digest news from the Trump-Xi meeting and await key earnings reports from major tech companies. Community chatter revolves around potential market reactions, with some anticipating a pullback and others expecting continued upward momentum. Sentiment appears mixed as participants analyze the implications of the meeting's outcome and upcoming financial results in the tech sector.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as traders digest potential implications from the Trump-Xi meeting, with discussions possibly involving NVIDIA's business in China and Blackwell chip authorization; the community is closely monitoring for updates. Meanwhile, autonomous vehicle innovation powered by NVIDIA tech was on display at #nvidiagtc, underscoring the company's expanding influence in AI and accelerated computing. Some analysts are discussing the company's high valuation and over dependence on specific clients.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as community members discuss its potential, particularly around new projects and meme coins built on the network. The launch of a Solana ETF is also generating excitement. Despite some volatility, there's a strong sense of optimism and community support driving conversation around the cryptocurrency.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending following its earnings report, which revealed strong revenue growth but a significant one-time tax charge impacting EPS. Community discussions revolve around the impact of increased AI spending and infrastructure costs on future profitability. Despite the earnings miss, some investors view the dip as a buying opportunity, citing the company's underlying strength and growth potential.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending as investors analyze the implications of its recent earnings report, with discussions focusing on the company's AI spending and Azure cloud growth. Community members are debating whether the post-earnings dip presents a buying opportunity, while also considering the broader context of potential price target adjustments from analysts. Some are expressing concern over Azure outages and management's guidance.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle $CMG is trending down as the community discusses disappointing Q3 earnings and lowered sales outlook, with concerns around declining customer traffic and operating margins. Many traders are pointing to high prices, smaller portions, and increased competition as potential factors. Some investors are considering this pullback an oversold buying opportunity, while others anticipate further declines.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending amid speculation around potential U.S.-China trade deals impacting rare earth exports, leading to community discussion on whether the stock will decline if a deal is reached.  Despite these concerns, many investors believe that MP's role as a key U.S. rare earth supplier, supported by government initiatives, positions it for long-term growth regardless of trade outcomes.  Bullish sentiment remains due to the company's potential in a sector vital for defense and technology, emphasizing the importance of domestic rare earth production.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is experiencing volatility, with the community debating recent price drops and potential market manipulation. Some traders see a bullish setup and buying opportunity, while others fear a deeper correction and potential bear market. The discussions also include macroeconomic factors like interest rate decisions and their impact on Bitcoin's trajectory.

statis crypto Watchlist

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation PR Newswire VANCOUVER, BC, Oct. 17, 2025...

Precision Oncology Approaches Drive $312B Market Transformation

Precision Oncology Approaches Drive $312B Market Transformation Precision Oncology Approaches Drive $312B Market Transformation PR Newswire VANCOUVER, Oct. 17, 2025 USA News Group News Commentary...

Next-Generation Targeted Therapies Reshape Precision Oncology Landscape

Next-Generation Targeted Therapies Reshape Precision Oncology Landscape Next-Generation Targeted Therapies Reshape Precision Oncology Landscape PR Newswire VANCOUVER, BC, Oct. 15, 2025 USA News Group...

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge PR Newswire VANCOUVER, BC, Oct. 15, 2025 Equity Insider News...

Shares of GT Biopharma had their best trading day in more than nine months after the company shared encouraging progress from its ongoing Phase 1 trial of GTB-3650, an experimental treatment for patients with relapsed or refractory CD33-positive blood cancers.The stock jumped 43.7% to $1.08 at Wednesday’s close, before slipping 10.5% in after-hours trading.The clinical-stage biotech company said enrollment in the study’s dose-escalation groups is progressing smoothly and remains “well on track.” Both patients in Cohort 3 have now begun treatment, with no signs of dose-limiting toxicities or tolerability issues so far.&nbsp;The company added that the first patient in Cohort 3 has shown “promising evidence of immune activation,” matching the levels of activity seen in patients from the two earlier, lower-dose groups.GT Biopharma's trial will evaluate the safety, pharmacokinetics/pharmacodynamics of GTB-3650, and evidence of immune activation. GTB-3650 will use the company's TriKE platform to recruit natural killer (NK) cells to fight cancer.The Phase 1 study can enroll up to 14 patients, with two people in each of seven planned dosing groups. The lowest dose starts at 1.25 micrograms per kilogram per day and could go up to 100 micrograms per kilogram per day in the highest group. Each patient will take the drug in two-week treatment cycles, with two weeks on therapy followed by two weeks off, for as long as four months if they continue to show signs of clinical benefit.If Cohort 3 is dosed without any problems, GT Biopharma anticipates dosing the first patient in Cohort 4 by the end of 2025. The dose level can be increased further if warranted. The company expects to provide an update on additional data by the end of 2025 and in the first quarter of 2026 as it moves to the higher dose levels in the trial that may yield more robust therapeutic effects.On Stocktwits, retail sentiment for GT Biopharma was ‘extremely bullish’ amid a 2,933% surge in 24-hour message volume.One user said that GT Biopharma shares appeared to be gaining strong upward momentum and could move toward double-digit levels.&nbsp;<stembedurl>https://stocktwits.com/Illbeyourhuckleberree/message/631516421</stembedurl>Another user commented that the company’s cancer therapy showed significant promise, with the potential for substantial long-term returns.<stembedurl>https://stocktwits.com/Djdanny/message/631566315</stembedurl><a href="https://stocktwits.com/symbol/GTBP">GT Biopharma’s stock</a> has declined 65% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

GT Biopharma’s stock (GTBP) has declined 65% so far in 2025. (Photo credit: Getty Images)

GT Biopharma Stock Logs Best Session In Over 9 Months On Promising Cancer Trial Data; Retail Eyes Double-Digit Rally

The biotech firm reported smooth progress in its Phase 1 trial of GTB-3650, with no safety issues and early signs of immune activation in the latest dosing group. 

Equity

Shares of GT Biopharma, Inc. surged more than 21% on Tuesday before slipping after-hours as investors reacted to the company's unexpected shift in its financing strategy.&nbsp;The announcement sent 24-hour message volume on Stocktwits skyrocketing by 18,700%, marking the highest spike among biotech stocks, with trading volume more than doubling from its daily average.The company said it had withdrawn its earlier Form S-1 registration, initially filed with the SEC in December, which sought approval for an automatic mixed securities shelf offering.&nbsp;The filing had not yet been declared effective, and no securities had been sold under the proposed offering.&nbsp;Instead, GT Biopharma opted for a direct warrant exercise agreement, securing immediate funds while offering new unregistered warrants to investors.Under the new arrangement, the company entered into definitive agreements to exercise existing warrants to purchase 302,069 shares of common stock, with an exercise price of $4.35 per share.&nbsp;The move is expected to generate approximately $700,000 in gross proceeds before deducting placement agent fees and offering expenses.The offering is anticipated to close by Thursday, with proceeds earmarked for working capital and general corporate purposes.On Stocktwits, retail investors' reactions were mostly positive to the company's financing shift.&nbsp;One user described the move as "going in the right direction."&nbsp;<stembedurl>https://stocktwits.com/Rassy40/message/605686808</stembedurl>Another pointed out that short sellers had expected dilution due to the S-1 registration, but they may now be forced to cover with the offering canceled.&nbsp;<stembedurl>https://stocktwits.com/Annet_why_net/message/605691704</stembedurl>However, some traders indicated they were still waiting for a more attractive entry point.Short interest on GTBP shares has jumped from 0.6% at the start of the year to 8.8% at the end of last week, per Koyfin data.Beyond the financing development, Roth MKM remains optimistic about GT Biopharma's clinical pipeline.&nbsp;The research firm expects the company to release initial data later this year from its Phase 1 trial evaluating GTB-3650, its therapy targeting CD33-expressing hematologic malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome.GT Biopharma ended 2024 with approximately $4 million in cash, which Roth MKM estimates is sufficient to fund operations into the second quarter of this year.&nbsp;The research firm maintained a 'Buy' rating on the stock, with an $11 price target, implying a potential fivefold increase from current levels.The company's stock has lost more than 17% year-to-date.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

GT Biopharma Retail Chatter Soars Most Among Biotechs After Financing Strategy Tweak

The company said it had withdrawn its earlier Form S-1 registration, initially filed with the SEC in December, which sought approval for an automatic mixed securities shelf offering.

Recap: GT Biopharma Q4 Earnings

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Remain in active dialogue with the FDA regarding IND clearance for GTB-3650, a 2nd generation nanobody TriKE for treatment of CD33+ leukemiaPhase 1 trial with GTB-3650 anticipated to start in 2H...

GT Biopharma trading halted, news pending

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

GT Biopharma announces 1-for-30 reverse stock split

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in San Francisco, CA.

GT Biopharma Inc

Will Apple (AAPL) beat quarterly earnings? 
 
*Powered by Polymarket

GTBP
GT Biopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GTBP News

GTBPGT Biopharma Inc